Related Experiment Video

Updated: Apr 27, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

11.3K

CDK6, a new target in MLL-driven leukemia

Iléana Antony-Debré1, Ulrich Steidl1

  • 1ALBERT EINSTEIN COLLEGE OF MEDICINE.

Blood
|July 5, 2014
PubMed

Insights

Researchers found that targeting the cell-cycle regulator CDK6 can inhibit the growth and promote differentiation of mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) cells.

Area of Science:

  • Hematology
  • Cancer Biology
  • Cell Cycle Regulation

Background:

  • Mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) is an aggressive subtype of leukemia.
  • Identifying novel therapeutic targets is crucial for improving treatment outcomes in MLL-AML.

Purpose of the Study:

  • To investigate the role of cell-cycle regulators in MLL-driven leukemogenesis.
  • To evaluate CDK6 as a potential therapeutic target in MLL-AML.

Main Methods:

  • Analysis of cell-cycle regulators in MLL-AML cell lines and patient samples.
  • Downregulation of CDK6 expression using genetic approaches.
  • Pharmacological inhibition of CDK6 activity.

Main Results:

  • CDK6 was identified as a key cell-cycle regulator in MLL-driven leukemic cells.
  • CDK6 downregulation or inhibition resulted in significant growth inhibition.
  • Pharmacological inhibition of CDK6 induced differentiation of MLL-AML cells.

Conclusions:

  • CDK6 is a promising therapeutic target for MLL-rearranged acute myeloid leukemia.
  • Targeting CDK6 may offer a novel treatment strategy for patients with MLL-AML.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.1K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

2.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K